

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1           1 (original): A lipid formulation, said lipid formulation comprising:  
2           a lipid phase, said lipid phase comprising a neutral lipid and a member selected  
3           from the group consisting of cationic lipids and mucoadhesive compounds;  
4           an aqueous phase; and  
5           a therapeutic agent.

1           2 (original): A lipid formulation in accordance with claim 1, wherein said neutral  
2           lipid is a phospholipid.

1           3 (original): A lipid formulation in accordance with claim 2, wherein said  
2           phospholipid is a soybean oil-based phospholipid.

1           4 (original): A lipid formulation in accordance with claim 2, wherein said  
2           phospholipid is a member selected from the group consisting of phosphatidylglycerols (PG),  
3           phosphatidylethanolamines (PE), phosphatidylserines (PS) and hydrogenated  
4           phosphatidylcholines (PC).

1           5 (original): A lipid formulation in accordance with claim 4, wherein said  
2           phospholipid is a phosphatidylcholine.

1           6 (original): A lipid formulation in accordance with claim 5, wherein said  
2           phosphatidylcholine is a member selected from the group consisting of Phospholipon 90H,  
3           Phospholipon 80H and mixtures thereof.

1                   7 (original): A lipid formulation in accordance with claim 1, wherein said lipid  
2 phase comprises a cationic lipid.

1                   8 (original): A lipid formulation in accordance with claim 7, wherein said  
2 cationic lipid is a member of the group consisting of stearylamine, DC-Cholesterol,  
3 dimethyldioctadecylammonium bromide, or 3B-[N',N'-dimethylaminoethane)-carbamol.

1                   9 (original): A lipid formulation in accordance with claim 1, wherein said lipid  
2 phase comprises a mucoadhesive compound.

1                   10 (original): A lipid formulation in accordance with claim 9, wherein said  
2 mucoadhesive compound is a member of the group consisting of Carbopol 934 P, polyaxomers,  
3 carbomers and plant lectins.

1                   11 (original): A lipid formulation in accordance with claim 1, wherein said  
2 aqueous phase is a member selected from the group consisting of sterile water, sterile saline and  
3 sterile, isotonic aqueous buffer solutions.

1                   12 (original): A lipid formulation in accordance with claim 11, wherein said  
2 aqueous phase is a sterile, isotonic aqueous solution buffered with borates, acetates, bicarbonates  
3 or phosphates in the pH range of 7.0 to 7.8.

1                   13 (original): A lipid formulation in accordance with claim 1, wherein said lipid  
2 formulation comprises about 0.001 to about 10.000 wt % of said lipid phase and about 90.000 wt  
3 % to about 99.999 wt % of said aqueous phase.

1                   14 (original): A lipid formulation in accordance with claim 1, wherein said lipid  
2 formulation comprises about 0.1 wt % of said lipid phase and about 99.0 wt % of said aqueous  
3 phase.

1               15 (original): A lipid formulation in accordance with claim 1, wherein said  
2 therapeutic agent is present in said aqueous phase.

1               16 (original): A lipid formulation in accordance with claim 1, wherein a  
2 therapeutically effective amount of said therapeutic agent is present in said lipid formulation.

1               17 (original): A lipid formulation in accordance with claim 1, wherein said lipid  
2 formulation is a liposome.

1               18 (original): A lipid formulation in accordance with claim 1, further comprising  
2 a preservative.

1               19 (original): A lipid formulation in accordance with claim 18, wherein said  
2 preservative is an antioxidant.

1               20 (original): A lipid formulation in accordance with claim 19, wherein said  
2 antioxidant is a member selected from the group consisting of tocoperol, tocopherol derivatives,  
3 butylated hydroxyanisole and butylated hydroxytoluene.

1               21 (original): A lipid formulation in accordance with claim 18, wherein said  
2 preservative is an anti-microbial agent selected from the group consisting of benzalkonium  
3 chloride, benzethonium chloride, chlorobutanol, phenylethyl alcohol and cetyl pyridinium  
4 chloride.

1               22 (original): A lipid formulation in accordance with claim 21, wherein said  
2 anti-microbial agent is chlorobutanol.

1               23 (original): A lipid formulation in accordance with claim 1, further comprising  
2 a modifying agent selected from the group consisting of cholesterol, stearylamine, cholesteryl  
3 hemisuccinate, phosphatidic acids, dicetyl phosphate and fatty acids.

1                   24 (original): A lipid formulation in accordance with claim 1, further comprising  
2        a wetting agent.

1                   25 (original): A lipid formulation in accordance with claim 24, wherein said  
2        wetting agent is a member selected from the group consisting of polyoxyethylene, sorbitan  
3        monolaurate and stearate.

1                   26 (original): A lipid formulation in accordance with claim 1, further comprising  
2        a thickening agent.

1                   27 (original): A lipid formulation in accordance with claim 26, wherein said  
2        thickening agent is a member selected from the group consisting of hydroxyethylcellulose,  
3        hydroxypropylmethylcellulose, methylcellulose, polyvinyl alcohol and polyvinylpyrrolidone.

1                   28 (original): A lipid formulation in accordance with claim 1, wherein said  
2        therapeutic agent is a non-steroidal anti-inflammatory drug (NSAID).

1                   29 (original): A lipid formulation in accordance with claim 30, wherein said  
2        NSAID is a member selected from the group consisting ketoprofen, flurbiprofen, ibuprofen,  
3        diclofenac, ketorolac, napafenac, amfenac and suprofen.

1                   30 (original): A lipid formulation in accordance with claim 30, wherein said  
2        NSAID is diclofenac.

1                   31 (currently amended): A method for treating an ophthalmic disorder in a  
2        mammal, said method comprising administering to the eye of said mammal a lipid formulation,  
3        said lipid formulation comprising:

4                   a lipid phase, said lipid phase comprising a neutral lipid and a member selected  
5        from the group consisting of cationic lipids and mucoadhesive compounds;  
6                   an aqueous phase; and

7                   a therapeutic agent in accordance with claim 1, wherein said therapeutic agent in  
8    said lipid formulation is useful for treating said ophthalmic disorder.

1                   32 (original): The method in accordance with claim 31, wherein said ophthalmic  
2    disorder is post-operative pain.

1                   33 (original): The method in accordance with claim 31, wherein said ophthalmic  
2    disorder is ocular inflammation.

1                   34 (original): The method in accordance with claim 33, wherein said ocular  
2    inflammation results from a member selected from the group consisting of iritis, conjunctivitis,  
3    seasonal allergic conjunctivitis, acute and chronic endophthalmitis, anterior uveitis, uveitis  
4    associated with systemic diseases, posterior segment uveitis, chorioretinitis, pars planitis,  
5    masquerade syndromes including ocular lymphoma, pemphigoid, scleritis, keratitis, severe  
6    ocular allergy, corneal abrasion and blood-aqueous barrier disruption:

1                   35 (original): The method in accordance with claim 31, wherein said ophthalmic  
2    disorder is post-operative ocular inflammation.

1                   36 (original): The method in accordance with claim 35, wherein said post-  
2    operative ocular inflammation results from a member selected from the group consisting of  
3    photorefractive keratectomy, cataract removal surgery, intraocular lens implantation and radial  
4    keratotomy.

1                   37 (original): The method in accordance with claim 31, wherein said ophthalmic  
2    disorder is a fungal or bacterial infection.

1                   38 (original): The method in accordance with claim 31, wherein said ophthalmic  
2    disorder is herpes ophthalmicus.

1                   39 (original): The method in accordance with claim 31, wherein said ophthalmic  
2    disorder is endophthalmitis.

1                  40 (original): The method in accordance with claim 31, wherein said ophthalmic  
2 disorder is intraocular pressure.

1                  41 (original): The method in accordance with claim 31, wherein said therapeutic  
2 agent is diclofenac.

1                  42 (original): The method in accordance with claim 41, wherein said diclofenac  
2 is diclofenac sodium.

1                  43 (original): A method for treating or preventing ocular inflammation,  
2 paracentesis-induced miosis, cystoid macular edema and mydriasis, said method comprising  
3 administering a therapeutically effective amount of one or more non-steroidal anti-inflammatory  
4 drugs encapsulated or contained within a liposome formulation, said liposome formulation  
5 comprising 0.001 to 10.000 wt% lipid phase, and 90.000 to 99.999 wt% aqueous phase.

1                  44 (original): The method in accordance with claim 43, wherein said liposome  
2 formulation is applied topically, resulting in the transcorneal or transscleral passage or  
3 introduction of one or more non-steroidal anti-inflammatory drugs into the eye.

1                  45 (original): The method in accordance with claim 43, wherein said lipid phase  
2 comprises 0.0 to 90.0 wt% of one or more active agents, 10.0 to 100.0 wt% phospholipid, 0.0 to  
3 20.0 wt% antioxidant, and 0.0 to 20% modifying agents; and said aqueous phase comprises 0.0  
4 to 10.0 wt% one or more active agents, 0.0 to 5.0 wt% anti-microbial preservative, and 90.0 to  
5 100.0 wt% aqueous solution.

1                  46 (original): The method in accordance with claim 45, wherein said active  
2 agent(s) are non-steroidal anti-inflammatory drugs.

1                  47 (original): The method in accordance with claim 46, wherein said non-  
2 steroidal anti-inflammatory drugs are selected from the group consisting of ketoprofen,  
3 flurbiprofen, ibuprofen, diclofenac, ketorolac, nepafenac, amfenac and suprofen.

1                   48 (original): The method in accordance with claim 47, wherein said non-steroidal  
2 anti-inflammatory drug is diclofenac.

1                   49 (original): The method in accordance with claim 43, wherein said ocular  
2 inflammation is a symptom of iritis, conjunctivitis, seasonal allergic conjunctivitis, post-  
3 operative inflammation, acute and chronic endophthalmitis, anterior uveitis, uveitis associated  
4 with systemic diseases, posterior segment uveitis, chorioretinitis, pars planitis, masquerade  
5 syndromes including ocular lymphoma, pemphigoid, scleritis, keratitis, severe ocular allergy,  
6 corneal abrasion, blood-aqueous barrier disruption or ocular trauma.

1                   50 (original): The method in accordance with claim 49, wherein said post-  
2 operative inflammation is caused by photorefractive keratectomy, cataract removal surgery,  
3 intraocular lens implantation or radial keratotomy.

1                   51 (original): A liposome formulation comprising: a therapeutic agent; 0.001 to  
2 10.000 wt% of a lipid phase; and 90.000 to 99.999 wt% of an aqueous phase.

1                   52 (original): The liposome formulation in accordance with claim 51, wherein  
2 said lipid phase comprises a phospholipid.